$27.440
-0.414 (-1.51%)收盘时
BRVE 同业对比
In the context of the broader market, BRVE competes directly with industry leaders such as VCEL and ZYME. With a market capitalization of $1.94B, it holds a significant position in the sector. When comparing efficiency, BRVE's gross margin of N/A stands against VCEL's 72.82% and ZYME's 100.00%. Such benchmarking helps identify whether Braveheart Bio, Inc. is trading at a premium or discount relative to its financial performance.
Braveheart Bio, Inc. 财务表现
The company has shown a year-to-date change of +52.44%, indicating strong market performance since its IPO. However, the P/E ratio is negative at -136.89, reflecting current losses, but this is typical for biotech firms in development stages.
Financials
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。